Glyxambi
Glyxambi is a diabetes medication containing Linagliptin + Empagliflozin, available as 25/5mg tablets.
- Category
- Diabetes
- Active ingredient
- Linagliptin · Empagliflozin
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 25/5mg
You will receive a quality generic equivalent, depending on stock.
Prescription rules on Glyxambi vary by country.
Details
- Conditions
- Type 2 diabetes mellitus
- Therapeutic Class
- DPP-4 Inhibitor, SGLT2 Inhibitor
- Pharmacological Class
- Gliptin, Gliflozin
- Minor Side Effects
- urinary tract infection, nasopharyngitis
- Moderate Side Effects
- genital infections, polyuria
- Dosage Forms
- Film-coated tablet
- Administration Route
- Oral use
- Prescription Status
- Available without prescription
- Originator
- Boehringer Ingelheim
- Onset Time
- 1–2 hours
- Duration
- 24 hours
- Storage Instructions
- Store at room temperature below 30°C.
- Drug Interactions
- insulin, sulfonylureas
- Age Restrictions
- Adults only.
What you will receive
Glyxambi is the originator brand name, made by Boehringer Ingelheim. We use it here to identify the medicine only; we are not affiliated with Boehringer Ingelheim and do not ship the original Glyxambi.
- You receive a generic equivalent: the same active ingredient (Linagliptin / Empagliflozin) at the same dose, mostly recognised Indian branded generics from vetted manufacturers.
- The exact brand supplied depends on what is in stock at the dispatching warehouse.
- A regulated generic matches the original ingredient for ingredient by legal standard.